Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2003 June;55(3) > Minerva Ginecologica 2003 June;55(3):217-20

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2003 June;55(3):217-20

language: Italian

Hormonal replacement therapy in menopause and cancer risk. An update

La Vecchia B., Franceschi S.


PDF  


The risk of breast cancer rises by about 2.3% per year of using estrogens and the risk is even higher in the case of combined therapy with estrogens and progestins; however the excess risk disappears 5 years after suspension of the treatment. The risk of endometrial tumour cancer is strongly associated with the use of estrogens but this increase is reduced or eliminated by the administration of progestinics for at least 12/14 days per month. The use of HRTs also seems to be directly associated with the risk of ovarian cancers, while they seem to exert a protective effect on colorectal neoplasms. The HRTs has favourable effects on bone metabolims, but they increase the risk of deep venous thrombosis and pulmonary embolism.

top of page

Publication History

Cite this article as

Corresponding author e-mail